Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner. DAS181, A Novel Sialidase Fusion Protein, Protects Mice from Lethal Avian Influenza H5N1 Virus Infection. J Infect Dis. 2007 Nov 15;196(10):1493-1499
Increasing resistance to currently available influenza antivirals highlights the need to develop alternate approaches for the prevention and/or treatment of influenza. DAS181 (Fludase), a novel sialidase fusion protein that enzymatically removes sialic acids on respiratory epithelium, exhibits potent antiviral activity against influenza A and B viruses. Here, we use a mouse model to evaluate the efficacy of DAS181 treatment against a highly pathogenic avian influenza H5N1 virus. When used to treat mice daily beginning 1 day before infection with A/Vietnam/1203/2004(H5N1) virus, DAS181 treatment at 1 mg/kg/day protected 100% of mice from fatal disease, prevented viral dissemination to the brain, and effectively blocked infection in 70% of mice. DAS181 at 1 mg/kg/day was also effective therapeutically, conferring enhanced survival of H5N1 virus-challenged mice when treatment was begun 72 h after infection. This notable antiviral activity underscores the potential utility of DAS181 as a new class of drug that is effective against influenza viruses with pandemic potential.
See Also:
Latest articles in those days:
- Outbreak of Highly Pathogenic Avian Influenza A(H5N1) Virus in Seals, St. Lawrence Estuary, Quebec, Canada 2 days ago
- Molecular characterization of influenza virus circulating in Nepal in the year 2019 2 days ago
- Seasonal antigenic prediction of influenza A H3N2 using machine learning 2 days ago
- Probable extinction of influenza B/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases 2 days ago
- Code to reproduce analysis in Nguyen et al, Emergence and interstate spread of highly pathogenic avian influenza A (H5N1) in dairy cattle. 3 days ago
[Go Top] [Close Window]